Annovis Bio

Annovis Bio announced FDA clearance for its drug buntanetap's Phase 3 study for Alzheimer’s, with trials planned for 2025. The drug also shows efficacy in Parkinson’s. The company secured $50 million through an ATM facility and aims for over $200 million for Phase 3 studies.

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.

Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.

Annovis CEO, Maria Maccecchini, discusses a breakthrough drug for neurodegenerative diseases like Alzheimer's and Parkinson's on Today's Marketplace, highlighting its potential to improve symptoms and protect nerve cells.

Annovis CEO, Maria Maccecchini, and Creighton University’s Scott Shipman discuss a promising drug for treating Alzheimer’s and Parkinson’s, emphasizing its potential to improve symptoms and reduce caregiver burden.

The article discusses the implementation of a Server-Side Rendering (SSR) service entry, identified by the file '/bundles/v1/views/latest/SSR-service-entry.c49d8207ea51fe4b43e4.js', within a web page structure.

Annovis Bio announced financial results for Q3 2024, highlighting FDA approval for Phase 3 studies of buntanetap in early AD, and filing of patents for combination therapies. The company secured $13.6 million in cash and expects to start the 6-month symptomatic study in Q1 2025.

Annovis Bio reported Q3 2024 financial results, including $13.6 million in cash, $4.4 million in Q3 operating expenses, and a net loss of $0.97 per share. The FDA granted clearance for pivotal Phase 3 studies of buntanetap in early Alzheimer's disease, with a 6-month symptomatic study starting Q1 2025. The company raised $4.4 million from ELOC facility and $7.1 million from warrant exercises, and filed three new patents for combination therapies involving buntanetap.

Key opinion leaders highlight unmet needs in Parkinson’s disease (PD) treatment, including lack of neuroprotective/disease-modifying therapies (DMTs) and non-motor symptom treatments. No DMTs are currently marketed; PD products focus on symptomatic relief. The PD drug development pipeline in 7 major markets emphasizes neuroprotective and DMTs, with 66% targeting these needs. Anti-alpha-synuclein therapies face skepticism due to safety concerns. There is also focus on non-motor symptoms, with 18% of the pipeline addressing symptom management beyond core motor symptoms.